PNC Financial Services Group
LRMR icon

PNC Financial Services Group’s Larimar Therapeutics LRMR Stock Holding History

PNC Financial Services Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$45 Hold
14
– – ﹤0.01% 5321
2026
Q2 		$43 Sell
14
-3
-18% -$12 ﹤0.01% 5176
2026
Q1 		$77 Hold
17
– – ﹤0.01% 5107
2025
Q4 		$65 Hold
17
– – ﹤0.01% 5088
2025
Q3 		$55 Hold
17
– – ﹤0.01% 5034
2025
Q2 		$49 Buy
+17
New +$39 ﹤0.01% 4865

Other funds holding LRMR

Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

PNC Financial Services Group's LRMR Position: Q3 2026 in Review

PNC Financial Services Group held its Larimar Therapeutics (LRMR) position steady in Q3 2026 at 14 shares worth $45. The position accounts for ﹤0.01% of the portfolio, ranked #5321.

PNC Financial Services Group first reported a position in LRMR in Q2 2025 and has held it in 6 quarters since. The position peaked at $77 in Q1 2026. 98 funds tracked by Wall St. Rank hold LRMR as of Q3 2026.

  • PNC Financial Services Group held 14 shares of Larimar Therapeutics worth $45 as of Q3 2026.
  • PNC Financial Services Group left its Larimar Therapeutics share count unchanged in Q3 2026.
  • Larimar Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #5321 holding.
  • PNC Financial Services Group first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • PNC Financial Services Group's Larimar Therapeutics position peaked at $77 in Q1 2026.
  • 98 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.